Yuhan Corp’s application to extend coverage for its 3rd-generation EGFR TKI non-small-cell lung cancer treatment Leclaza (lasertinib)' as a first-line treatment is making rapid progress.

After passing the Health Insurance Review and Assessment Service review, all that remains is drug price negotiations with the National Health Insurance Corporation.

On the 12th, the HIRA held the 2023 11th Drug Reimbursement Evaluation Committee meeting and deliberated on the adequacy of reimbursement for drugs including Leclaza.

Leclaza, which was the only one on the agenda for reimbursement expansion on this day, was recognized as adequate for reimbursement.

Accordingly,